-
Ozone, Efferocytosis, and Neuropathic Pain
2026-08-26
A 2024 Frontiers in Immunology study identifies macrophage efferocytosis as a modifiable component of neuropathic pain and links ozone treatment to the AMPK/Gas6-MerTK/SOCS3 pathway. In chronic constriction injury mice and bone-marrow-derived macrophages, ozone improved apoptotic-cell clearance, reduced inflammatory signaling, and alleviated mechanical hypersensitivity, while pharmacological pathway inhibition weakened these effects.
-
Fluoroalkane Polymers for mRNA Cancer Vaccines
2026-08-26
The reference study introduces fluoroalkane-grafted polyethylenimine (F-PEI) as a relatively simple carrier for therapeutic mRNA. Its self-assembled nanovaccines improved intracellular delivery, promoted TLR4-associated dendritic-cell activation and antigen presentation, and produced antitumor activity in ovalbumin and neoantigen mouse models, particularly when combined with immune checkpoint blockade.
-
Cisapride (R 51619) in Cardiac Screening
2026-08-25
Cisapride (R 51619) connects 5-HT4 receptor biology with hERG-linked cardiac risk in iPSC-cardiomyocyte workflows. This guide translates high-content imaging, electrophysiology, and troubleshooting principles into a practical assay strategy for cardiac arrhythmia research.
-
NSC 87877: Practical Shp2 Inhibitor Workflows
2026-08-25
NSC 87877 is a potent Shp2 inhibitor for separating phosphatase-dependent signaling from upstream receptor events in EGF, microglial, leukemia, and inflammatory pain models. This guide converts SHP2–NLRP3 findings from ischemic-stroke research into practical assay designs, controls, and troubleshooting strategies.
-
17-AAG and HSP90: Assay-Ready Cancer Biology
2026-08-24
17-AAG (Tanespimycin) provides a powerful way to interrogate HSP90-dependent oncogenic signaling, client-protein stability, and apoptosis. This article combines cancer biology with assay lessons from a landmark NINJ1–norovirus study to improve causal interpretation without overstating cross-domain evidence.
-
PID1, Oxysterols, and Macrophage Fate in Cancer
2026-08-24
The reference study identifies PID1 as an immunometabolic checkpoint that controls LDL uptake, cholesterol oxidation, and tumor-associated macrophage state. Its findings suggest that redirecting sterol metabolism toward 5α,6α-epoxycholesterol and 7β-hydroxycholesterol can improve CD8+ T-cell surveillance and enhance 5-fluorouracil responses.
-
SARS-CoV-2 N Protein, GADD34, and Atypical Foci
2026-08-23
The reference study identifies a stress-granule-associated mechanism by which SARS-CoV-2 nucleocapsid protein suppresses GADD34-dependent innate immunity. Its central finding is that nucleocapsid-driven N+/G3BP1+ atypical foci sequester GADD34 mRNA, impair IRF3 nuclear localization, and support viral replication.
-
Ricin-Triggered Bystander Necroptosis in Lung Epithelium
2026-08-22
Kempen and colleagues demonstrate that ricin-injured monocytic cells can transmit a soluble death signal to lung epithelial cells, converting primary toxin injury into bystander necroptosis. Their U937-to-A549 model identifies released ricin, Fas ligand, HMGB1, RAGE signaling, and reactive oxygen species as components of this inflammatory cascade, with implications for interpreting toxin-associated lung damage.
-
Gastrin I (Human): From Receptor Biology to Translation
2026-08-22
A translational framework for using Gastrin I (human) to connect CCK2 receptor signaling and proton pump activation with human-relevant gastric and intestinal models, including hiPSC-derived organoids for gastrointestinal physiology studies, pharmacokinetic evaluation, and gastrointestinal disorder research.
-
Ademetionine in Neurological Disorders: Evidence
2026-08-21
The 1994 review by Bottiglieri, Hyland, and Reynolds positioned ademetionine, or S-adenosylmethionine (SAMe), as a biochemical link between one-carbon metabolism, neurotransmitter regulation, and neurological disease. Its main contribution was an integrated interpretation of mechanistic, deficiency-related, and early clinical evidence, while also emphasizing that therapeutic conclusions remained preliminary in several disorders.
-
Chemerin–NTS Signaling Raises Sympathetic Drive
2026-08-20
This 2024 study identifies a chemerin–CMKLR1–NADPH oxidase pathway in the caudal nucleus tractus solitarius that increases sympathetic nerve activity, blood pressure, and heart rate. Pharmacological tests further indicate that the downstream paraventricular nucleus response depends more strongly on NMDA receptors than on AMPA/kainate receptors, refining interpretation of glutamatergic signaling in neurocardiovascular circuits.
-
Tumor-Targeted T Cell Engineering for Cold Tumors
2026-08-20
He et al. develop a TERT promoter-controlled plasmid that co-localizes LIGHT-mediated immune remodeling with membrane-anchored anti-CD3 activity in tumors. The approach improves T-cell recruitment, intratumoral function, and persistence while enhancing checkpoint inhibitor and CAR-T responses across several immune-cold solid-tumor models.
-
TAK1 Inhibition at the Metabolic–Inflammatory Nexus
2026-08-19
A translational perspective on how (5Z)-7-Oxozeaenol enables precise TAK1 interrogation across inflammatory and metabolic-stress biology, with practical guidance for experimental design, validation, and interpretation.
-
Pyridostigmine and Placental Necroptosis in Preeclampsia
2026-08-19
The reference study identifies placental necroptosis as a modifiable component of preeclampsia-like pathology and shows that pyridostigmine improves disease-associated outcomes in a reduced uterine perfusion pressure rat model. Pharmacological reversal by α-bungarotoxin links these effects to α7 nicotinic acetylcholine receptor signaling and provides a mechanistic framework for studying non-neuronal cholinergic regulation of placental injury.
-
Measuring Drug Response Beyond Cell Viability
2026-08-18
Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability to clarify how cancer drugs combine growth inhibition and cell killing. Its central implication is practical: drug-response studies should measure proliferation and death as related but noninterchangeable outcomes, ideally with attention to their different timing.